Deposit of biological material under Budapest treaty

Introduction

The deposit of biological material under the Budapest Treaty refers to the formal submission of microorganisms and other biological materials to recognised International Depositary Authorities (IDAs) for patent-related purposes. The Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure was adopted in 1977 and entered into force in 1980.

The treaty establishes an international system under which a biological material deposited with one recognised authority can be accepted by patent offices in multiple contracting states. This avoids the need for applicants to deposit the same microorganism separately in every country where patent protection is sought.

The treaty is particularly important for biotechnology, microbiology, genetic engineering, pharmaceutical research, industrial enzymes, and biological inventions because certain inventions cannot be adequately described through written patent specifications alone.

Meaning and purpose of biological material deposit

Biological material deposit is the process of submitting a biological sample to an authorised institution that preserves and maintains the material under prescribed conditions.

In conventional patent applications, inventors generally describe their inventions through written specifications, drawings, and technical information. However, some biotechnology inventions involve microorganisms that cannot be sufficiently identified or reproduced through written descriptions.

The Budapest Treaty addresses this difficulty by recognising deposits made with approved international institutions.

Its major objectives include:

Ensuring reproducibility of biological inventions.

Providing reliable preservation of deposited microorganisms.

Avoiding repeated deposits in different countries.

Supporting international patent applications.

Improving scientific verification and patent examination.

International legal framework

1. Budapest Treaty, 1977

The Budapest Treaty provides the principal international framework for recognising deposits of microorganisms for patent procedures.

Article 3: Recognition and effects of deposit

Contracting states recognise the deposit of microorganisms made with an International Depositary Authority for patent procedures. This recognition avoids requiring additional deposits merely because patent protection is sought in different contracting states.

Article 4: New deposit

The treaty provides a procedure for making a new deposit where the original biological material is no longer available or the depositary authority cannot furnish a sample.

Article 6: International Depositary Authorities

An institution must satisfy prescribed requirements before obtaining the status of an International Depositary Authority. These requirements include maintaining the necessary scientific facilities, expertise, and preservation capabilities.

Article 7: Acquisition of IDA status

The treaty establishes the procedure through which an institution may acquire International Depositary Authority status.

The treaty's implementing Regulations also prescribe requirements concerning deposits, viability testing, storage, and furnishing of samples.

Biological materials covered by the treaty

The Budapest Treaty primarily concerns microorganisms and biological materials that can be deposited and maintained by recognised depositary institutions.

Examples include:

Bacteria.

Fungi and yeasts.

Certain biological cultures.

Microorganisms used in pharmaceutical manufacturing.

Genetically modified microorganisms.

Other biological materials accepted by an International Depositary Authority.

The treaty does not automatically cover every biological material. Its application depends on whether the material can be accepted and maintained by an authorised depositary institution under the applicable rules.

Procedure for depositing biological material

The deposit process generally involves the following stages.

1. Identification of biological material

The applicant identifies the microorganism or biological material forming an essential part of the invention.

2. Selection of an International Depositary Authority

The applicant selects an IDA that accepts the particular type of biological material.

3. Submission of the sample

The biological sample is submitted with the required technical information, documentation, and applicable fees.

4. Viability and identity testing

The depositary authority examines whether the material is suitable for deposit and performs relevant testing according to its procedures.

5. Issuance of deposit information

After accepting the deposit, the authority issues a deposit receipt and assigns an accession number.

6. Reference in the patent application

The patent applicant includes the depositary institution's name, accession number, and relevant deposit details in the patent specification as required by applicable patent law.

Indian legal framework

India is a member of the Budapest Treaty and recognises the international deposit system for relevant patent procedures.

The Patents Act, 1970, provides the domestic legal framework for patent protection involving biological inventions.

1. Section 3(j)

Section 3(j) excludes plants and animals in whole or any part thereof, other than microorganisms, from patentability, subject to the statutory wording. Essentially biological processes for production or propagation of plants and animals are also excluded.

2. Section 10(4)

Section 10(4) requires a patent specification to fully and particularly describe the invention, its operation or use, and the method by which it is performed.

Where biological material cannot be adequately described and is not publicly available, the applicant may need to deposit it with an International Depositary Authority and disclose the relevant deposit information.

3. Patent Rules, 2003

Rule 13(8) contains requirements concerning disclosure of the source and geographical origin of biological material used in an invention.

The applicable deposit and disclosure requirements must be followed when filing patent applications involving biological materials.

Relationship between biological deposits and patent protection

The Budapest Treaty does not itself grant patent rights. It only establishes an internationally recognised deposit mechanism for patent procedures.

Patentability remains governed by the applicable national patent laws.

For example, an invention involving a deposited microorganism must still satisfy relevant patentability requirements, including novelty, inventive step, and industrial applicability under Indian patent law.

Furthermore, a biological deposit does not automatically establish ownership over the microorganism or remove obligations under biodiversity legislation.

Important case laws

1. Dimminaco A.G. v. Controller of Patents and Designs, 2002 SCC OnLine Cal 564

The Calcutta High Court considered whether a process for preparing a vaccine involving a living organism could qualify for patent protection under the Patents Act, 1970.

The Court rejected the view that a process involving a living organism was automatically excluded from patentability merely because the resulting product contained living material.

The decision is important for biotechnology patents involving microorganisms and biological processes. It also highlights the importance of adequate disclosure of biological inventions.

2. Novartis AG v. Union of India (2013) 6 SCC 1

The Supreme Court examined the patentability requirements under Section 3(d) of the Patents Act in relation to a pharmaceutical invention.

Although the case did not directly concern the Budapest Treaty, it established important principles concerning the patentability of biotechnology-related and pharmaceutical inventions. It confirms that compliance with disclosure and deposit procedures does not automatically establish patentability.

3. Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2019) 3 SCC 381

The Supreme Court considered patent-related disputes concerning genetically modified cotton seeds and biotechnology inventions. The Court set aside the Delhi High Court's decision and remanded the matter for fresh consideration.

The case is relevant to biological patent disputes because it demonstrates the complexity of determining patent protection for biotechnology innovations. It did not directly decide the legal requirements of Budapest Treaty deposits.

4. J. Mitra & Co. Pvt. Ltd. v. Kesar Medicaments Pvt. Ltd. (2008) 10 SCC 368

The Supreme Court considered patent infringement and the statutory framework governing patent rights. Although it did not involve a biological deposit, it provides general guidance on the enforcement of patent rights arising from biotechnology and pharmaceutical inventions.

5. Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013)

The United States Supreme Court examined whether naturally occurring human DNA could be patented merely because it had been isolated. The Court held that naturally occurring DNA is not patentable merely through isolation, while synthetically created complementary DNA may qualify, subject to applicable patent requirements.

The decision is relevant to the limits of patent protection for biological materials, although it does not concern the Budapest Treaty deposit procedure.

Legal challenges and practical risks

Biological material deposits raise several legal and scientific challenges.

Material preservation: Depositary authorities must maintain the deposited material and ensure its continued viability.

Confidentiality: Access to deposited samples must follow treaty procedures and applicable patent rules.

Sample contamination: Contamination or deterioration may affect the reproducibility of the invention.

Patent disclosure: Incorrect accession numbers or inadequate deposit information may create difficulties during patent examination.

Ownership disputes: Depositing biological material does not automatically establish ownership or unrestricted rights over the material.

Biodiversity compliance: Biological resources obtained from India may require compliance with the Biological Diversity Act, 2002, as amended, depending on the material, applicant, and activity.

Conclusion

The Budapest Treaty provides an important international mechanism for depositing biological materials for patent procedures. It simplifies international patent filing by allowing one recognised deposit to be accepted across multiple contracting states. In India, the Patents Act, 1970, and Patent Rules, 2003, provide the relevant domestic framework for biological invention disclosure and patent examination. Judicial decisions such as Dimminaco A.G. v. Controller of Patents and Designs demonstrate the importance of recognising the technical characteristics of biological inventions. However, a biological deposit alone does not guarantee patentability or ownership. Effective protection requires proper scientific documentation, preservation, statutory disclosure, and compliance with applicable biodiversity requirements.